Join
Live feed
·
PRReleasevia Quantisnow
GH Research PLC logo

GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction

ByQuantisnow·Wall Street's wire, on your screen.
GHRS· GH Research PLC
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GHRS (GH Research PLC) and more on Quantisnow.